|drug1648||Interleukin 6 (IL6) Antagonist and corticosteroids Wiki||1.00|
|D016638||Critical Illness NIH||0.13|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
There is one clinical trial.
The cytokine storms mediated by over production of proinflammatory cytokines have been observed in a large population of critically ill patients infected with COVID-19. Patients diagnosed with cytokine storms progress to cardiovascular collapse, multiple organ dysfunction and death rapidly. Therefore, early identification, treatment and prevention of the cytokine storms are of crucial importance for the patients. Immuomedulator such as interleukin-6 (IL-6) antagonist, emerged as an alternative treatment for COVID-19 patients with a risk of cytokine storms recently. In this study, we aimed to evaluate the safety and efficacy of anti-IL6 alone vs anti-IL6 corticosteroid combination in patients with COVID-19 pneumonia
Description: The median ventilator-free days will be calculated as calendar days with no ventilator support to day 28 . Participants who die before day 28 are assigned zero free days.Measure: Ventilator-Free Days Time: Up to Day 28
Description: From Intubation to extubation date and off Mechanical Ventilation or until ICU discharge, death, or 28 days whichever occurs first.Measure: Median duration of ventilation Time: Up to Day 28
Description: Ratio of arterial oxygen partial pressure (PaO2 in mmHg) to fractional inspired oxygen (FiO2)Measure: Median change in the PaO2/FiO2 Time: Up to Day 28
Description: The median vasopressor-free days will be calculated as calendar days with no vasopressor support to day 28. Participants who die before day 28 are assigned zero free days.Measure: Vasopressor-Free days Time: Up to Day 28
Description: To compare ICU LOSMeasure: Duration of ICU Stay Time: Up to 28 days
Description: To compare hospital LOSMeasure: Duration of Hospital Stay Time: Up to 28 days
Description: Death that occurs during 28 daysMeasure: Mortality Rate Time: Up to Day 28
Description: adverse events that occurs during 28 daysMeasure: Percentage of participants with adverse events [transaminitis, hyperglycemia] Time: Up to 28 days
Description: Concentration of inflammatory markersMeasure: Concentration of Ferritin, IL6, D dimer, fibrinogen, C-reactive protein (CRP), Lactate dehydrogenase (LDH) and absolute lymphocyte count and their correlation with the effectiveness of the treatment Time: Up to 28 days
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports